DINAMIQS obtains ExcellGene’s HEKExpress® and HEK2Express® cell line technologies for viral vector GMP manufacturing

DINAMIQS, a Siegfried company, today announced a licensing agreement with ExcellGene to access its HEKExpress® and HEK2Express® suspension cell line technologies. These will be used in GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for both in-vivo and ex-vivo gene therapies.

Eduard Ayuso, Chief Technical Officer at DINAMIQS: “We have extensively evaluated the performance of ExcellGene’s HEKExpress® and HEK2Express® suspension cell lines in terms of growth rates and viral vector productivity. We were impressed by their excellent growth rate and stable doubling times over multiple passages in commercial serum-free media. Both lentiviral and adeno-associated vector yields were at the high end of reported market values. In addition, we observed a superior purity profile, particularly in the ratio of full to empty particles across multiple AAV productions.”

Maria Wurm, CEO of ExcellGene, commented: “We are delighted to collaborate with DINAMIQS and support their mission to advance gene therapy manufacturing with reliable, scalable solutions. Our HEKExpress® and HEK2Express® cell line platforms have been designed for high performance and robustness across viral vector types. Partnering with DINAMIQS allows us to see these technologies reach patients faster by enabling consistent, high-yield production from research to GMP scale.”